NUCB2 is an EF-hand Ca 2+ binding protein that has been implicated in various physiological processes like calcium homeostasis, hypothalamic regulation of feeding and TNF receptor shedding. In our previous study we identified NUCB2 as a potential tumour antigen eliciting autoantibody responses in 5.4% of gastric cancer patients but not in the healthy individuals. The current study aimed to elucidate the molecular mechanism underlying NUCB2 immunogenicity and to gain an insight into the physiological functions of NUCB2 in the stomach. mRNA expression analysis demonstrated that NUCB2 is ubiquitously expressed in normal tissues, including lymphoid tissues, and downregulated in gastric tumours when compared with the adjacent relatively normal stomach tissues. The search for molecular alterations resulted in the identification of novel mRNA variants transcribed from an alternative promoter and expressed predominantly in gastric cancers. Western blot analysis demonstrated that the protein levels correspond to mRNA levels and revealed that NUCB2 is phosphorylated in gastric mucosa. Furthermore, a 55 kDa isoform, generated presumably by yet an unidentified post-translational modification was detected in gastric tumours and AGS gastric cancer cells but was absent in the relatively normal gastric mucosa and thereby might have served as a trigger for the immune response against NUCB2. Staining of stomach tissue microarray with anti-NUCB2 antibody revealed that it is expressed in the secretory granules of chief cells and in the cytoplasm of parietal cells in the functioning gastric glands which are lost in atrophic glands and tumour cells. Hence we propose that NUCB2 may be implicated in gastric secretion by establishing an agonist-releasable Ca 2+ store in ER or Golgi apparatus, signalling via heterotrimeric Gα proteins and/or mediating the exocytosis of the secretory granules.
N ucleobindin 2 (NUCB2 or NEFA) is a ubiquitously expressed EF-hand Ca 2+ binding protein that may be implicated in various physiological processes, however, its functional role and mechanism of action are poorly understood. So far, two nucleobindins -NUCB1 (or Calnuc, Nuc) and NUCB2 have been identified in humans (Wendel et al. 1995; Barnikol-Watanabe et al. 1994) . They share 61.65% amino acid identity and a characteristic composition of functional domains -a signal peptide, a Leu/Ile rich region, basic amino acid rich region including putative bipartite nuclear localisation signal, two Ca 2+ binding EF-hand domains separated by acidic amino acid rich region and a leucine zipper (Figure 1 ) (Barnikol-Watanabe et al. 1994; Miura et al. 1992) . Genes encoding NUCB1 and NUCB2 are located in 19q13.2-q13.4 and 11p15.1-p14, respectively, and are deemed to be derived from a common four-domain EF-hand ancestor (Karabinos et al. 1996) . Within the cell both are located in the cytoplasmic and Golgi luminal pools, both are secreted into extracellular space and interact with other proteins in a calciumdependent manner (Lavoie et al. 2002; Lin et al. 2000; Morel-Huaux et al. 2002; Taniguchi et al. 2000; Islam et al. 2006) . Both nucleobindins were reported to interact with the postmitotic growth suppressor Necdin in neuronal cytoplasm (Taniguchi et al. 2000) and have been shown to constitute a Ca 2+ storage pool in Golgi (Lin et al. 1999; Kroll et al. 1999; Morel-Huaux et al. 2002) . NUCB1 interacts with cyclooxygenases in COS-1 cells (Ballif et al. 1996) and with G protein Gαi3 in the cytoplasm of rat kidney cells (Lin et al. 2000) , and acts as a negative regulator in ATF6-mediated unfolded protein response (Tsukumo et al. 2007) . It is secreted via constitutive secretory pathway in AtT20 pituitary cells (Lavoie et al. 2002) . NUCB2 has been shown to form a calcium-dependent complex with ARTS-1 that mediates release of TNF receptor to the extracellular compartment from human vascular endothelial cells (Islam et al. 2006) . Furthermore, nesfatin-1 -the N terminal 82 amino acid peptide generated by post-translational processing of NUCB2 in rat hypothalamus -was recently shown to be involved in feeding regulation and suggested to suppress appetite via leptin-independent signalling (Oh et al. 2006) and is upregulated by serotonin receptor agonists (Nonogaki et al. 2008) .
In a previous study we identified NUCB2 as an antigen eliciting autoantibody production in gastric cancer patients (Line et al. 2002) by exploiting the SEREX (serological identification of antigens by recombinant expression cloning) approach (Sahin et al. 1997) . The screening of gastric cancer-derived cDNA expression library with allogeneic serum resulted in the identification of 5 different serum-reactive phage clones, including Zg4 encoding the 31-179 aa region of NUCB2 (Figure 1 ). Anti-NUCB2 antibodies were found exclusively in patients with gastric cancer and not in colon and breast cancer patients or healthy donors. No immune responses against NUCB2 have been reported so far, while NUCB1 has been shown to be overexpressed in 59.4% of colon cancer specimens and elicit autoantibody responses in 11.5% of the cases (Chen et al. 2007) . Furthermore, Nucb1 is excessively produced in lupus-prone mice and induces autoantibody response against itself and a number of other lupus-associated autoantigens when injected in normal BALB/c mice, and the antibody production is mediated by autoreactive CD4 + T cells (Kanai et al. 1995; Kubota et al. 2001) .
The aim of the current study is to identify the putative molecular alterations underlying the immunogenicity of NUCB2 in gastric cancer patients and to get an insight into its physiological role in gastric mucosa.
Materials and Methods

Tissue and serum samples and cell line
Gastric cancer and adjacent relatively normal tissue samples from 36 patients (Table 1) undergoing surgery at the Latvian Oncology Centre were collected intraoperatively and one part of each specimen was immediately submerged in RNAlater (Ambion) and subsequently used for RNA extraction while another was embedded in paraffin blocks. Sera were collected from the same patients whose tissue specimens were collected and from another 20 gastric cancer patients, 23 colorectal and 11 breast cancer patients and 13 patients with chronic atrophic gastritis at the time of diagnosis. Sera from 36 healthy individuals were obtained from the Genome Database of the Latvian population. This study was approved by the Central Committee of Medical Ethics of Latvia and the tissue samples and sera were collected after the patients' informed consent was obtained.
AGS gastric cancer cell line was purchased from ECACC and grown in monolayer culture in Ham's F12 supplemented with 2 mM glutamine and 10% FBS (Invitrogen). 
Serological analysis
The frequency of anti-NUCB2 antibody responses in allogeneic sera was determined by plaque assay as described previously (Line et al. 2002) . Briefly, E. coli XL1 blue cells were transfected with the lambda phages by spotting 20-30 pfu of Zg4 phage side by side with non-recombinant phage directly on an agar plate and the phage arrays were screened with 1:200 diluted sera, which have been previously preabsorbed with E. coli-phage lysates.
The presence of antibodies against gastric parietal cell (GPC) H+/K+ ATPase antigen was tested semi-quantitatively in the sera from 13 atrophic gastritis patients and 16 gastric cancer patients by enzyme linked immunosorbent assay exploiting AUTOSTAT™ Anti-Gastric Parietal Cell kit (Hycor Biomedical) following manufacturer's instructions.
Real-time RT-PCR analysis
NUCB2 mRNA expression pattern was analysed in a panel of normal tissues consisting of whole bone marrow, brain, colon, heart, kidney, lung, pancreas, skin, spleen, stomach, testis, thymus and trachea (BioCat, Ambion) and compared between gastric cancer and adjacent non-cancerous tissues by real-time RT-PCR. Total RNA was isolated from RNAlater preserved cancerous and adjacent normal tissue specimens using TRI reagent (Sigma) according to the manufacturer's instructions. Four micrograms of total RNA were used to synthesise first-strand cDNA by random hexamer priming using First-Strand cDNA Synthesis Kit (MBI Fermentas). To choose the appropriate reference genes for each tissue panel, a set of seven candidate reference genes (TBP, POLR2A, YWHAZ, ACTB, GAPDH, PGK1, TUB3A) were tested for their mRNA expression stability in the given panel and three most stable genes (TUB3A, ACTB and POLR2A for normal tissue panel and ACTB, TBP and POLR2A for gastric cancer and the adjacent tissue panel) were determined by using the openaccess software GeNorm (http://medgen.ugent.be/ jvdesomp/genorm). These genes were used to calculate the factor which was applied for the normalisation of the obtained NUCB2 mRNA expression data.The following gene-specific primers were used for the amplification of NUCB2 and the reference genes: NUCB2 forward 5'-TCAAGCAAGT-GATTGATGTGC-3', reverse 5'-TCAGGATTCA GGTGGTTTAGG-3'; ACTB forward 5'-AGTGT-GACGTGGACATCCG-3', reverse 5'-AATCTCATC TTGTTTTCTGCGC-3; TUB3A forward 5'-TATG-GCAAGAAGTCCAAGCTG-3', reverse 5'-TACCAT-GAAGGCACAATCAGAG-3'; POLR2A forward 5'-GGGTCATCTTCCCAACTGGAG-3', reverse 5'-CACCAGCTTCTTGCTCAATTCC-3' and TBP forward 5'-CCACTCACAGACTCTCACAAC-3', reverse 5'-CTGCGGTACAATCCCAGAAC-3'. In all experiments 1/30 of each RT mixture was amplified in a total reaction volume of 20 µL containing 2 pmol of each primer and 10 µL SYBR Green mix (ABgene) exploiting 7500 Real Time PCR System (Applied Biosystems). All reactions were performed in duplicates.
5' RLM-RACE and RT-PCR analysis
Full-length 5' end sequences of NUCB2 cDNA were cloned from 3 gastric cancer specimens using FirstChoice TM RLM-RACE kit (Ambion) as recommended by the manufacturer. Briefly, 10 µg of total RNA underwent 5' phosphate removal from uncapped RNAs by Calf Intestinal Phosphatase treatment and next, cap structures from full-length mRNAs were removed with Tobacco Acid Pyrophosphatase leaving a free 5' phosphate. mRNA molecules containing 5' phosphate were 9 Original Paper subjected to the ligation of RNA adapters to their 5' ends. Random-primed reverse transcription was performed with subsequent nested PCR using NUCB2-specific reverse primers (5'-TCAGGATT CAGGTGGTTTAGG-3' for PCR 1 and 5'-CTAT-GTCTGCTTTCTGGAGC-3' for PCR 2) and adapter-specific forward primers. PCR products were cloned using InsTAclone TM PCR Product cloning Kit (MBI Fermentas) and multiple clones were sequenced. The expression of the identified NUCB2 transcript variants in normal tissues (brain, liver, heart, kidney, lung, trachea, spleen, colon, stomach, testis and ovary) (Ambion) and paired gastric cancer and adjacent normal tissues was analysed by RT-PCR using alternative forward primers located in exon 1 5'-CAGGTTTGT-GCGCTGGACG-3' and in exon 1a 5'-AGAAATCTC-CTGGAATCAAGG-3' and common reverse primer 5'-CTATGTCTGCTTTCTGGAGC-3'. GAPDH was used as the endogenous control. cDNA synthesis was carried out as described above and 1/15 of RT mixture was amplified in a total reaction volume of 20 µL containing 10 pmol of each primer, 200 µM dNTPs and 2 U of Taq polymerase (MBI Fermentas) in the following cycling conditions: 1 min at 94°C, 30 s at 58°C and 45 s at 72°C.Twenty five cycles of amplification were performed for GAPDH, 27 for NUCB2 transcripts containing exon 1 and 35 for those containing exon 1a.
Western blot analysis
NUCB2 protein levels in gastric cancer, adjacent normal tissues and AGS cell line were analysed by Western blotting. Total protein was isolated from tissue samples using TRI reagent (Sigma) simultaneously with RNA according to manufacturer's instructions.Ten µg of total protein were resuspended in Laemmli sample buffer, denatured for 5 min at 100°C and separated by 10% SDS-PAGE. Proteins were electroblotted onto Protan nitrocellulose membrane (Whatman) and stained with Ponceau S solution to verify equal protein loading. The membrane was destained, blocked with 5% (w/v) fatfree milk in TBS and probed with 1:200 diluted mouse anti-NUCB2 monoclonal antibody, kindly provided by Dr. Shitsu Barnikol-Watanabe (Gottingen, Germany). Antigen-antibody complexes were detected using HRP-conjugated goat antimouse secondary antibody (Sigma) (diluted 1:5000 in TBS) and ECL detection system (GE Healthcare) according to the manufacturer's instructions. In parallel, secondary antibody alone was used for probing to provide the negative control.
Dephosphorylation and deglycosylation experiments
On-line open access softwares (http://www. cbs.dtu.dk/services and http://www.expasy.ch/tools) were used for the prediction of protein phosphorylation and glycosylation sites. To assess the phosphorylation status, protein samples were treated with 1 U of SAP (MBI Fermentas) for 1 h at 37°C and then subjected to Western blot analysis as described above. Deglycosylation was carried out using Enzymatic deglycosylation kit (Glyko) according to the manufacturer's instructions. The protein extracts were denatured by heating at 100°C for 5 min in SDS and β-mercaptoethanol and then incubated with N-Glycanase (5U/mL), Sialidase A (5U/mL), O-Glycanase (1.25U/mL), β(1-4)-Galactosidase (2 U/mL) and β-N-Acetylglucosaminidase (40 U/mL) for 3 hours at 37°C and analysed by Western blot. Bovine Fetuin was treated in parallel as a positive control.
Immunohistochemistry
To investigate the NUCB2 expression in different regions of stomach and various gastric lesions, human tissue array containing a total of 63 cores from multiple sites in normal stomach, and a total of 80 cores from superficial gastritis, mild, moderate and severe chronic atrophic gastritis with intestinal metaplasia as well as grade I-III adenocarcinoma was purchased from Cybrdi and processed using mouse anti-NUCB2 monoclonal antibody (at 1:20 dilution in PBS, 1% BSA) kindly provided by Dr. Shitsu Barnikol-Watanabe (Gottingen, Germany) and Mouse UniTec ABC kit (Calbiochem) according to the manufacturer's instructions.To study NUCB2 protein expression in gastric cancers, 4 µm thick sections were prepared from formalin-fixed, paraffin-embedded gastric cancer and adjacent normal tissue specimens from the same patients whose tissues were used for RT-PCR and Western blot analyses and mounted on poly-L-lysine-coated slides, deparaffinised in xylene and rehydrated by placing in 100%, 95%, 80%, 70%, 50% ethanol and PBS. Antigen retrieval was performed by boiling in microwave in 10 mM sodium citrate buffer for 15 min. Next, the sections were washed in PBS and the endogenous peroxidases were quenched with 0.3% hydrogen peroxide in methanol for 30 min at RT. Then the sections were blocked with 5% BSA in PBS, 0.5% Tween-20 for 1 h and incubated with mouse anti-NUCB2 monoclonal antibody, at 1:20 dilution in PBS, 1% BSA overnight at 4°C. Slides were washed in PBS, 0.1% Tween-20 and then incubated with HRP-conjugated goat anti-mouse secondary antibody (Sigma) at 1:100 dilution for 1 h at RT. To visualise antigen-antibody complexes, sections were stained for 10 min with DAB solution (Sigma) and counterstained with Mayer's haematoxylin. Sections were dehydrated in 70%, 96% and 100% ethanol for 3 min each, cleared in carboxylol and covered with mounting balsam and cover slips. In parallel, negative controls were performed by substituting primary antibody with nonimmunised mouse serum.
Results
Humoural responses to NUCB2 are gastric cancerspecific
The frequency of autoantibodies against NUCB2 was determined by plaque assay in the sera from healthy individuals (n=36) and patients of gastric cancer (n=56), colorectal cancer (n=23), breast cancer (n=11) and chronic atrophic gastritis (n=13). Anti-NUCB2 antibodies were found in 3 gastric cancer patients (5.36%), including the patient whose serum was used for searching of tumour antigens by allogeneic SEREX screening but not in the healthy individuals and patients with colorectal or breast cancer or gastritis (χ 2 test: p=0.158 relative to healthy donors).
NUCB2 mRNA is differentially expressed in normal tissues and downregulated in gastric cancer
NUCB2 mRNA expression pattern was examined by real-time RT-PCR in a panel of RNAs derived from various normal tissues and gastric cancer and adjacent normal tissues (Table 1) .This demonstrated that NUCB2 mRNA is predominantly expressed in pancreas, while its level is 2-3 fold lower in spleen, thymus, bone marrow, testis and stomach and more than 8 fold lower in the remaining normal tissues analysed (Figure 2 A) . The comparison of mRNA levels between paired gastric cancer and relatively normal tissues showed that it is 2-95 fold downregulated in 28 out of 36 cases analysed (Figure 2 B) 
5' RLM-RACE analysis reveal novel NUCB2 transcript variants
To search for alternative transcription and translation initiation sites and splice variants of NUCB2, 5' RLM-RACE analysis was performed resulting in the identification of three novel transcript variants of NUCB2 differing in the exon composition at the 5' end of the mRNA (transcript variants b, c and d in Figure 3 A) (deposited in GenBank, accession numbers EU039831, EU039832 and EU039833). Identification of an alternative first 134 bp exon (1a) located 7408 bp upstream from the conventional first exon suggests the existence of a distal NUCB2 promoter.The other transcript variants differ in an alternative 5' splice site of the exon 1 that is elongated by 20 bp, and an insertion of alternative exon 2a between exons 2 and 3. Although alternative exons 1a and 2a introduce two independent upstream translation initiation sites, they are followed by coterminous stop codons and therefore can not give rise to alternative protein isoforms (Figure 3 A) . The expression of the NUCB2 transcript variants a and b representing proximal and distal promoters, respectively, was examined by RT-PCR in various normal tissues and gastric cancer and adjacent normal tissues from seven patients. This demonstrated that in the normal tissues the distal promoter is used mainly in testis and ovary (Figure 3 B) . However, as its detection required 35 cycles of amplification while NUCB2-a was detectable after 27 cycles, it likely is a low-abundance transcript variant. This is also consistent with the results of Northern blot revealing a single NUCB2-specific band (data not shown). Usage of the distal promoter was also detected in more than a half of gastric tumours analysed while it was low or undetectable in the adjacent normal tissues (Figure 3 C) . Interestingly, with a single exception, the expression of NUCB2-b transcripts was higher in the tumours with markedly reduced NUCB2-a expression.
Western blot analysis reveal posttranslational modifications of NUCB2
In order to determine whether the NUCB2 protein level corresponds to its mRNA level, protein extracts of 16 paired gastric cancer and adjacent normal tissues were analysed by Western blot. This showed that the mRNA level correlated with the protein level in all cases analysed and confirmed the downregulation of NUCB2 in cancerous tissues (Figure 4 A) . It also revealed the presence of additional 52, 53, 55 and 57 kDa species of NUCB2, furthermore 55 and 57 kDa bands were present in 9 out of 16 tumour tissue specimens, including Ga3T -tumour tissue from the patient whose serum was used to search for antigens by SEREX, and AGS gastric cancer cells but not in the relatively normal stomach tissues. Since no putative protein isoforms generated by alternative splicing were identified, we concluded that these bands likely represent post-translationally processed forms of NUCB2. To identify the nature of these modifications, NUCB2 sequence was analysed using tools for the prediction of post-translational modifica-12 Z. Kalnina et al. tions at www.expasy.ch/tools/ and www.cbs.dtu.dk/ services. NetPhos 2.0 Server revealed a number of putative Ser, Thr and Tyr phosphorylation sites. To examine the phosphorylation status of NUCB2, the protein extracts were treated with shrimp alkaline phosphatase and subjected to Western blot analysis (Figure 4 B) . The treatment removed 53 and 52 kDa bands in normal tissues and 52 and 57 kDa bands in tumour tissue thus showing that these bands represented phosphorylated forms of NUCB2. However, 52 kDa band in some normal tissue specimens and 55 kDa band in tumours was not affected by the treatment with phosphatase suggesting that they were derived from an alternative post-translational modification. No putative N-glycosylation, acethylation, myristoylation or palmitoylation sites were found by sequence analysis. Although NUCB1 has been shown to undergo Oglycosylation (Lavoie et al. 2002) and 31 Ser and Thr residues were found in NUCB2 sequence, none of them were predicted as potential glycosylation sites by NetOGlyc 3.1 Server.To examine the glycosylation status of NUCB2, the protein extracts were treated with Sialidase A and O-Glycanase but the treatment did not result in the shift of mobility (results not shown). To remove more complex Olinked structures containing β(1-4)-linked galactose or β-linked N-acetylglucosamine, the extracts were treated with β(1-4)-Galactosidase and β-NAcetylglucosaminidase prior to the O-glycanase treatment, yet this also did not result in the increase in mobility of NUCB2 bands.
Localisation of NUCB2 in normal gastric epithelium and gastric lesions
To determine which cell types express NUCB2 in normal gastric epithelium and various gastric lesions, a gastric tissue microarray was stained with the anti-NUCB2 monoclonal antibody.This demonstrated that NUCB2 is predominantly localised in the secretory vesicles of chief cells and at lower levels in the cytoplasm of parietal cells in the stomach body ( Figure 5 A-C), whereas mucous cells were NUCB2-negative (Figure 5 A, C) . 
Antibodies against NUCB2 are not associated with anti-parietal cell antibodies
Autoantibodies to acid secreting gastric parietal cells (GPC) are involved in the aetiology of autoimmune and atrophic gastritis that are known to be precancerous lesions (Correa 1992) . Since NUCB2 expression was localised in gastric parietal cells, we hypothesised that NUCB2 may represent one of the antigens recognised by anti-parietal cell antibodies (APCA). As GPC H + /K + ATPase is the dominant antigen used to detect the presence of APCA, we expected anti-NUCB2 and anti-H + /K + ATPase antibodies to coincide in the sera from patients with gastritis and cancer. Four of 13 atrophic gastritis patients' and one of 16 gastric cancer patients' serum samples tested were positive for APCA, however, none of them had anti-NUCB2 antibodies. Similarly, the patients having anti-NUCB2 antibodies were negative for APCA thus demonstrating that induction of anti-NUCB2 response is not associated with the autoimmune processes against GPC.
Discussion
It has been generally assumed that cancer-associated expression pattern (expression restricted to cancers and testis, the cell type from which the cancer originated, foetal tissues or neurons, overexpression), and a variety of molecular alterations including mutations, translocations and splicing defects may underlie the immunogenicity of SEREX-defined antigens, however, only in a few cases such alterations have been found and demonstrated to induce the immune response (Chen YT 2004; Tureci et al. 1999; Kalnina et al. 2005; Pfreundschuh 2000) . Other mechanisms that may render tumour cell proteins immunogenic are altered posttranslational modifications (Canelle et al. 2005; Robinson et al. 2002; Brichory et al. 2001) , aberrant subcellular localisation resulting for instance from virus infection (Dong et al. 1994) or altered binding partners of normal self-proteins, or their localisation on the surface of apoptotic tumour cells as shown in the case of β-actin in medullary breast cancer (Hansen et al. 2001 ).
In the current study we examined the molecular alterations that may underlie the IgG responses against NUCB2 in gastric cancer patients. The mRNA distribution analysis showed that NUCB2 is expressed in several normal tissues including spleen, thymus and bone marrow. Usually CD4 + T cells recognising antigens that are continuously present in lymphoid tissues are tolerased (Zinkernagel and Hengartner 2001; Bos et al. 2005) . Since the activation of B cells and Ig class switch to generate IgG class antibodies requires signals from activated TH cells, it is unlikely that the antibodies are directed against the wild-type NUCB2 protein. Furthermore, NUCB2 mRNA and protein levels were found to be downregulated in the majority of gastric tumour tissues when compared to adjacent normal tissues. As the overexpression is supposed to be the most frequent immunogenic stimulus for SEREX-defined antigens, this finding seemed surprising. However, multiple downregulated antigens eliciting cancer-specific immune responses have been identified by SEREX before, including p14.5 in hepatocellular carcinoma (Stenner-Liewen et al. 2000) , Seb4B and HDAC5 in colon cancer (Scanlan et al. 2002) and SNT-1/BR-41 in breast cancer (Scanlan et al. 2001) . We propose that the immunogenicity of the downregulated antigens is likely to be elicited by the alterations at the DNA, mRNA or protein level resulting in the structural changes of the protein that may give rise to novel epitopes. Hence, some of them may turn out to be tumour suppressors. In fact, the NUCB2 gene is localised to locus 11p15.1-p14, known to be frequently deleted in ovarian and bladder tumours (Kiechle-Schwarz et al. 1994; Shaw and Knowles 1995) .
In a previous study we searched for somatic mutations in NUCB2 cDNA by sequencing the complete protein coding region amplified from the tumour tissue of the patient with anti-NUCB2 antibodies. Although several polymorphisms, including ACA insertion/deletion (Gln 402) were found, none of them turned out to be somatic mutations (Line et al. 2002) .
Next, we searched for novel splice variants or transcription initiation sites by applying 5' RLM-RACE to three gastric cancer specimens that resulted in the identification of an alternative distal promoter and three novel transcript variants differing in the exon composition at the 5' end of the mRNA, yet none of them could encode for a novel protein isoform. Although the mRNAs transcribed from the newly identified alternative promoter appeared to constitute only a minor fraction of the total NUCB2 mRNA pool, the distal promoter was considerably more active in gastric cancers than in the adjacent normal tissues, particularly in those cases where the total NUCB2 level was strongly downregulated. Hence the usage of the alternative promoter may represent a compensatory mechanism in tumour cells when the transcription from the conventional promoter is shut off. Alternative 5'UTRs have been shown to play an important role in the post-transcriptional regulation of gene expression by affecting downstream splicing events, translation efficacy, RNA sorting and localisation (Brevini et al. 2007; Smith 2008; Cazzola and Skoda 2000; Tsuda et al. 2000) .
In two gastric cancer patient samples, the usage of the distal promoter correlated with the presence of 55 and 57-kDa bands detected by Western blot in gastric tumours but not in adjacent normal tissues. Dephosphorylation experiments demonstrated that the 57 kDa band represents phosphorylated form of the 55 kDa NUCB2 isoform, which by itself is likely to represent novel post-translationally modified isoform.To identify the nature of the modification, we carried out enzymatic deglycosylation, yet this did not affect the mobility of the 52 kDa band in normal tissues and the 55 kDa band in tumours. This treatment should remove most of common O-linked sugars, however it does not cleave several rare O-linked structures such as N-acetylgalactosamine found in mucins or mannose, for example, therefore the glycosylation of NUCB2 can not be definitely ruled out. Although we did not detect any NUCB2-positive cancer cell by immunohistochemistry, the 55 kDa band was detected in AGS gastric cancer cells by Western blotting that implies this isoform is produced by cancer cells not by plasma cells or the remaining functional gastric glands yet at the level undetectable by immunohistochemistry. Alterations in the glycosylation patterns and other post-translational modifications (PTMs) are frequently found in various tumours and have been shown to trigger immune responses to self or tumour proteins (Ohmori and Kanayama 2005; Suriano et al. 2005; Doyle et al. 2006; Doyle and Mamula 2005) . However it remains to be determined whether the altered PTM acts as a trigger for the immune response against NUCB2 and whether the transcript variant containing the alternative 5'UTR is associated with the altered PTM.
Alternatively, the autoantibody production could be elicited by the cleavage of NUCB2 during apoptosis as it has been demonstrated for apoptotic cleavage product of BARD1 (Gautier et al. 2000) . In fact, NUCB2 was recently shown to be cleaved by caspases and the cleavage sites are located at one of the EF-hand motifs (Figure 1 ) (Valencia et al. 2008) .
The identification of multiple functionally unrelated interaction partners and their implication in various processes such as Ca 2+ homeostasis (Kroll et al. 1999; Morel-Huaux et al. 2002; Taniguchi et al. 2000; Lin et al. 1999) , Gα protein mediated signalling (Lin et al. 2000) , unfolded protein response (Tsukumo et al. 2007 ), TNFR1 shedding (Islam et al. 2006 ) and hypothalamic feeding regulation (Oh et al. 2006; Nonogaki et al. 2008) suggests that nucleobindins are multifunctional proteins having various tissue-specific functions. So far, nothing is known about their function in stomach. The staining of stomach tissue sections with anti-NUCB2 antibody revealed its expression in the chief cells and parietal cells but not in mucous and muscle cells while it is not clear whether it is expressed in G and ECL cells. The main function of chief and parietal cells is the secretion of pepsinogens and gastric acid, respectively. Both secretion processes are coupled and mediated by the intracellular Ca 2+ signalling (Hou and Schubert 2006; Remy et al. 2007; Kimura et al. 2001; Gritti et al. 2000) . The localisation of NUCB2 in the secretory granules of chief cells and its loss in atrophic glands suggests a role in the secretion processes by establishing an agonistreleasable Ca 2+ store in ER or Golgi apparatus, signalling via heterotrimeric Gα proteins and/or mediating the exocytosis of the secretory granules.
It also would be of interest to investigate whether the nesfatin 1, the 1-82 aa peptide generated by a proteolytic cleavage of NUCB2 in hypothalamus recently shown to act as a satiety molecule via the serotonin system (Oh et al. 2006; Nonogaki et al. 2008) , is also processed and secreted in gastric mucosa as it was shown for other hypothalamic peptides that regulate food intake.
Furthermore, NUCB2 has been shown to have an essential role in the generation of soluble extracellular TNF receptors (TNFR1) through binding to ARTS-1 (aminopeptidase regulator of TNFR1 shedding) extracellular domain in a calciumdependent manner, at least in vascular endothelial cells (Islam et al. 2006) . If the same mechanism is operational in the parietal cells, the loss of NUCB2 expression during the progression of gastritis would abolish TNFR1 release, thereby rendering the parietal cells more susceptible to TNF-α induced apoptosis and thus increasing the severity of atrophy and inflammation.
In summary, we made an attempt to elucidate the molecular mechanism underlying NUCB2 immunogenicity in gastric cancer patients. Novel transcript variants differentially expressed in cancerous tissues and a novel cancer-associated posttranslationally modified NUCB2 isoform were identified, however, no conclusive evidence was gained to prove their association with the immunogenicity of NUCB2. Nevertheless, this study for the first time gained an insight into the physiological functions of NUCB2 in the stomach -it showed that NUCB2 is phosphorylated and expressed in the secretory granules of chief cells and in the cytoplasm of parietal cells in the functioning gastric glands and further we propose the potential role of NUCB2 in the signalling leading to the secretion of gastric acid and pepsinogens. It also would be of interest to investigate whether the loss of NUCB2 is implicated in the progression of inflammation and atrophy mediated by TNF signalling.
